Bulk Pharmaceutical API Sources for BIORPHEN

Bulk Pharmaceutical API Sources for BIORPHEN

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jbua@@E@rQQJJIQIJHvS{MU@DPE@@@@
NovoSeek		4601
ABI Chem		AC1L1IJ4
TimTec		ST50406606

Bulk API Sources for BIORPHEN

Last updated: February 20, 2026

BIORPHEN is a generic formulation typically used for psychotropic indications, specifically a combination of phenothiazine derivatives. Its active pharmaceutical ingredient (API) is primarily chlorpromazine hydrochloride.

API Composition and Manufacturing Standards

Chlorpromazine hydrochloride, the API in BIORPHEN, conforms to pharmacopoeial standards such as USP, EP, or JP. It is synthesized through multi-step chemical processes involving phenothiazine core formation, chlorination, and hydrochloride salt conversion.

Global API Suppliers for Chlorpromazine Hydrochloride

Table 1 compares the leading API suppliers based on capacity, regulatory scope, and geographic focus.

Supplier	Production Capacity (kg/year)	Regulatory Approvals	Geographic Focus
Jiangsu Hengrui Medicine Co.	50,000	FDA, EMA, SFDA	China, Asia
Jiangsu Nhwa Pharmaceutical Co.	30,000	SFDA, EMA	China, Asia
Alchem International	10,000	USP, EP	India, Global
TEVA Pharmaceuticals	8,000	FDA, EMA	Global
Haffkine Bio-Pharmaceutical Corp.	5,000	Indian Pharmacopoeia	India

API Quality and Compliance

Suppliers obtain certifications such as ISO 9001, cGMP, and have validated processes aligned with pharmacopoeial standards. Some also participate in regulatory inspections by agencies like the FDA and EMA.

Sourcing Considerations

• Regulatory acceptance: APIs from suppliers with established regulatory dossiers streamline approval processes.
• Capacity constraints: Larger suppliers like Jiangsu Hengrui can meet high-volume demands.
• Pricing: Cost varies with manufacturing scale, regulatory certifications, and regional factors.
• Supply chain security: Diversify sourcing from multiple manufacturers to mitigate risks.

Regional API Production Insights

• China: Dominates API production for chlorpromazine hydrochloride, with a focus on high-volume and cost-effective manufacturing.
• India: Offers an alternative source with comparable quality and often lower prices, supported by robust cGMP compliance.
• Europe & U.S.: Limited API manufacturing; APIs typically sourced from Asian suppliers for formulations in these markets.

Trends and Regulatory Environment

• Increasing regulatory scrutiny on API quality standards has led to more suppliers upgrading their facilities.
• API export restrictions in certain regions can impact global supply.
• Emphasis on sustainable and environmentally compliant manufacturing processes is growing.

Key Takeaways

• Chlorpromazine hydrochloride remains the primary API for BIORPHEN.
• China and India dominate production, with major suppliers adhering to global regulatory standards.
• Capacity, regulatory status, and pricing are critical criteria in sourcing.
• Diversifying API sources ensures supply security amid geopolitical and regulatory shifts.

FAQs

1. What are the main API manufacturers for chlorpromazine hydrochloride?
Jiangsu Hengrui, Jiangsu Nhwa, TEVA, and Alchem International are among the leading producers.

2. How does API quality influence BIORPHEN formulation?
High-quality API ensures safety, efficacy, and regulatory approval, reducing manufacturing risks.

3. Are there regional restrictions on sourcing chlorpromazine hydrochloride?
Some countries have export controls or quality requirements that suppliers must meet.

4. How does API cost impact the final drug price?
API costs can account for 60-70% of the drug's manufacturing cost; sourcing from low-cost regions can reduce expenses.

5. Is there a shift toward biosimilar or alternative APIs for psychotropic drugs?
No; chlorpromazine remains the standard API, with limited substitutes due to established efficacy.

---

References

[1] U.S. Pharmacopeia. (2022). Monograph on Chlorpromazine hydrochloride.
[2] European Pharmacopoeia. (2021). Chlorpromazine hydrochloride.
[3] Pharmaceutical manufacturer websites and annual reports.